Poxel ^Public

September 2021. Poxel's main goal is to develop innovative treatments for chronic serious diseases with metabolic pathophysiology, focusing on non-alcoholic steatohepatitis (NASH) and rare disorders. Their lead program, Imeglimin, targets mitochondrial dysfunction and has been approved for type 2 diabetes in Japan. They also have other drug candidates in mid-stage development for NASH and are evaluating their platforms for other metabolic diseases. Poxel aims to launch Phase 2a proof-of-concept studies in ALD early 2022.